Annual Report 2013

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that the Annual Report for 2013 now is available at the company’s website: www.medivir.com.

   
Annual Report 2013

http://www.medivir.se/v5/images/pdf/2014/Medivir_2013_ENG.pdf

   
“2013 was, without doubt, one of the most eventful years in Medivir’s 25-year history! The biggest single event during the year was the marketing approval of simeprevir – a pharmaceutical for the treatment of patients with chronic hepatitis C that we have helped develop. The approval has allowed the launch of simeprevir in Japan, Canada and the USA. Hepatitis C infected patients can now be treated using a drug that we have helped discover and develop. It is a source of great satisfaction to all Medivir employees, myself included, that we have developed a pharmaceutical all the way from a concept to a new treatment that can cure people and save lives,” said Medivir’s CEO, Maris Hartmanis, in his CEO’s Statement in this year’s Annual Report.”

   
About Medivir

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

Tags:

About Us

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model and the drug development as well as the commercialization is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.